), and (4) group A Ϫ D Ϫ (patients without diarrhea who did not receive antibiotics; n p 60 ). Stool samples were plated on MacConkey agar and K. oxytoca was identified using a standard test kit. n p 111 Clostridium difficile was detected by a toxin A/B antigen test. K. oxytoca strains were tested for cytotoxicity with use of cell-culture assays.
Results. In 15 of 371 stool samples, K. oxytoca strains were isolated during the study period. There was no significant difference in the distribution of K. oxytoca among the 4 study groups. Six of the 15 strains were found to be toxin producing. Three of the toxin-producing strains caused antibiotic-associated hemorrhagic colitis. No case of nonhemorrhagic antibiotic-associated diarrhea due to toxin-producing K. oxytoca was detected.
Conclusion. K. oxytoca is not the causative agent of nonhemorrhagic antibiotic-associated diarrhea. This is in contrast to the distinct clinical entity of antibiotic-associated hemorrhagic colitis. Testing for K. oxytoca is therefore only warranted for patients who experience bloody diarrhea during antibiotic therapy.
Antibiotic-associated diarrhea frequently occurs during antibiotic treatment. In severe cases, it can be a significant cause of morbidity and mortality, especially in elderly hospitalized patients. The mechanisms by which antibiotics lead to antibiotic-associated diarrhea are diverse, ranging from pharmacologic effects on gut motility to disturbance of the function of the indigenous intestinal flora and overgrowth by pathogenic microorganisms [1] . Clostridium difficile is the most common pathogenic microorganism to cause antibiotic-associated diarrhea, although it accounts for only 10%-20% of all cases [2] . The clinical spectrum of C. difficile-associated disease ranges from diarrhea without colitis to antibiotic-associated pseudomembranous colitis and fulminant colitis [2] .
Antibiotic-associated hemorrhagic colitis (AAHC) is a distinct form of antibiotic-associated diarrhea, in which no C. difficile is detected. AAHC is characterized by sudden onset of bloody diarrhea during antibiotic therapy, often in combination with severe abdominal cramps [3] . On endoscopy, the key macroscopic feature of AAHC is segmental distribution of mucosal hemorrhage and mucosal edema localized predominantly in the right colon. Recently, toxin-producing Klebsiella oxytoca was identified as the causative agent of this disease entity [3] . It has also been suggested that K. oxytoca is associated with severe colitis without preceding antibiotic therapy [4, 5] and the aggravation of Crohn disease [6] . Whether K. oxytoca plays a role in the development of nonhemorrhagic antibiotic-associated diarrhea has not been investigated.
The aim of our study was to elucidate the pathogenetic relevance of K. oxytoca in adult patients with antibiotic-associated diarrhea and to establish whether routine testing for K. oxytoca is warranted in these patients. Stool specimens were cultured to isolate K. oxytoca from patients who had antibiotic-associated diarrhea and from control subjects. In addition, K. oxytoca isolates were tested for cytotoxin production.
PATIENTS AND METHODS
Patient selection. Study patients were recruited in a 280-bed department of internal medicine at a university hospital from November 2006 through February 2008. Patients were included only once during their hospital stay and always provided written informed consent. The protocol was approved by the ethics committee of the Medical University of Graz (Graz, Austria).
Patients were surveyed during clinical rounds for the presence of antibiotic-associated diarrhea, diarrhea, or antibiotic treatment in the absence of diarrhea. Antibiotic treatment was defined as the receipt of any oral or intravenous antibiotic in therapeutic doses for у1 day, as described elsewhere [7] . Antibiotic-associated diarrhea was defined as у3 mushy or watery stools per day during or as long as 2 months after antibiotic treatment [8] . A total of 371 patients who met the inclusion criteria were recruited into 4 study groups: (1) Patients receiving antibiotic treatment because of suspected acute bacterial diarrhea (i.e., diarrhea due to Salmonella, Shigella, Campylobacter, or Yersinia species) were excluded. In addition, patients who met у1 of the following criteria were excluded from the study: inflammatory bowel disease, lactose intolerance, short bowel syndrome, hematooncologic disease, receipt of chemotherapy within the previous 2 months, abdominal surgery during the past 2 months, or hospitalization in the intensive care unit during the previous 30 days. Demographic, clinical, and laboratory data were extracted from charts and computerized databases. The diagnosis of AAHC was made on the basis of the clinical history (use of antibiotics before the onset of bloody diarrhea) and findings on endoscopy and histology that were typical of segmental hemorrhagic colitis, according to definitions published elsewhere [3] .
Microbiological analysis. Stool samples were plated on MacConkey agar plates (bioMérieux). Klebsiella species were identified using the API 20E test (bioMérieux). Stool speciments were tested for C. difficile toxins A and B with use of a rapid detection assay (Immunocard Toxins A & B; Meridian Bioscience Quantitative cultures were performed as described elsewhere [7] from stool specimens positive for K. oxytoca that had been stored at Ϫ70Њ. In brief, the stool samples were diluted 1:10 with saline, stirred in a stool homogenizer and again diluted 1:1000 and 1:10,000 with saline. One hundred microliters of each dilution was transferred onto a MacConkey agar plate and plated evenly with a sterile glass swab. After 24 h of incubation at 37ЊC, suspected colonies were identified using API 20E, were counted, and colony forming units (CFU) per mL of stool sample were calculated.
Cytotoxin assays. All strains that were identified as K. oxytoca by the API 20E test were tested for the production of cytotoxin with use of cell-culture assays. Cytotoxic effects were assessed by microscopic examination (cell rounding and cell death) and colorimetric investigation (MTT tetrazolium method), as described elsewhere [3, 9, 10] .
Statistical analysis. Statistical analysis was performed using Cramer's V test and Mann-Whitney test, where appropriate, with use of SPSS software, version 9.0 (SPSS). A P value of !.05 was considered to indicate statistical significance. ), Salmonella species were detected in the stool samples of 4 60 patients, whereas 3 were positive for Campylobacter species. In 37 patients of this group, no diarrheal pathogen was detected. Sixteen patients in this group were not tested for bacterial pathogens other than K. oxytoca and C. difficile.
RESULTS

Group
DISCUSSION
K. oxytoca was recently found to be the causative agent of AAHC, a distinct form of antibiotic-associated diarrhea in which C. difficile is absent [3] . Whether K. oxytoca plays a role in nonhemorrhagic antibiotic-associated diarrhea had not been investigated until now. In our study, there was no significant difference in the distribution of K. oxytoca species in the 4 Table 3 . Toxin production and quantitiy of Klebsiella oxytoca detected in patients' stool specimens. study groups, demonstrating that K. oxytoca is not associated with nonhemorrhagic antibiotic-associated diarrhea. Although a total of 371 patients were investigated, this finding should be interpreted with caution because the prevalence of K. oxytoca was low in all study groups. Eighteen patients in group A + D + experienced bloody diarrhea. Three of these 18 patients received a diagnosis of AAHC on endoscopy, and toxin-producing K. oxytoca was isolated from stool samples in all 3 cases. All 3 patients in our study experienced a sudden onset of bloody diarrhea in combination with abdominal cramps during antibiotic therapy with amoxicillin-clavulanate, similar to what has been reported elsewhere [3] . Concomitant intake of nonsteroidal anti-inflammatory drugs, which has been considered to be an etiologic cofactor in AAHC [3] , was verified in all 3 patients. In addition to the 3 cases of AAHC, K. oxytoca was isolated from the stool specimen of only 1 other patient in group A + D + . This isolate did not produce cytotoxin, and the patient received a diagnosis of C. difficile-related pseudomembranous colitis. Our results indicate that routine testing for K. oxytoca in stool samples is warranted only for patients who are experiencing bloody diarrhea during antibiotic therapy.
In our study, antibiotic-associated diarrhea was caused by C. difficile in 11% patients, which is consistent with other studies [2] . Klebsiella species were found in 15% of patients in the control group A Ϫ D Ϫ . This result is comparable to that of another study performed in a healthy Dutch population (aged 50-80 years), which detected Klebsiella species in 12% of stool samples [11] . K. oxytoca was identified in 4% of patients in our control group A Ϫ D Ϫ , which is comparable to other recently published findings [3] . Interestingly, only 1 toxin-producing K. oxytoca strain was found in the control group A Ϫ D Ϫ . Quantitative stool culture revealed a low concentration of this pathogen in the stool specimen. This patient was considered to be an asymptomatic carrier of toxin-producing K. oxytoca. We hypothesize that induction of colitis by K. oxytoca is associated with increased colony counts of this pathogen triggered by antibiotic therapy.
In group A Ϫ D + , 2 K. oxytoca isolates were found to be toxin producing. In 1 of these patients (patient 345), K. oxytoca was simultaneously isolated from a urine specimen during routine culture (K. oxytoca count, CFU/mL). This isolate dem- 6 1 ϫ 10 onstrated no toxin production (data not shown). Because no other cause of diarrhea could be established, K. oxytoca-with an intestinal colony count of CFU/mL-might have caused nonbloody diarrhea in this patient without preceding antibacterial therapy. In the second patient's stool sample, !10 CFU/mL of K. oxytoca was found, indicating that it was extremely unlikely that this patient's diarrhea was caused by K. oxytoca. In contrast, K. oxytoca could be detected in large quantities in all of the patients who had AAHC (mean K. oxytoca count in stool sample, CFU/mL) in our study, sug-6 3.6 ϫ 10 gesting that the administration of antibiotics alters the indigenous intestinal flora and promotes the growth of K. oxytoca. Large quantities of this microorganism apparently produce large amounts of cytotoxin, thus causing hemorrhagic colitis. It is currently unknown whether patients who develop AAHC are colonized with K. oxytoca prior to antibiotic therapy, with antibiotic therapy leading to K. oxytoca overgrowth with toxin production, or whether patients who develop AAHC are newly infected with K. oxytoca.
It has to be noted that the receipt of fluoroquinolones was more common in group A + D + than in group A + D Ϫ . In accordance with a recent investigation [12] , 4th-generation fluoroquinolones, the predominant quinolones used in our study, were obviously associated with a higher risk of antibiotic-associated diarrhea among our study population.
In conclusion, our study demonstrates that K. oxytoca is not associated with nonhemorrhagic antibiotic-associated diarrhea in adult patients. Routine testing for K. oxytoca is therefore only warranted for patients who are experiencing bloody diarrhea during antibiotic therapy.
